Moderna (MRNA) Stock Surges After Unveiling Cancer and Autoimmune Pipeline Push

TLDR

• Moderna stock jumped ~13% to $67.50, its highest close since September 2024, following its investor day.
• The company announced its first in vivo CAR-T program, mRNA-6007, targeting autoimmune diseases like lupus, with clinical development planned for 2027.
• An FDA advisory panel voted 9-0 in favor of Moderna’s flu vaccine candidate for adults 50+, with an FDA decision expected August 5, 2026.
• Analyst Andrew Tsai (Jefferies) raised his price target to $53 from $45, while Piper Sandler’s Edward Tenthoff lifted his to $77, maintaining an Overweight rating.
• Wall Street’s consensus remains Hold, with an average price target of $45.42 — implying downside from current levels.

Moderna (MRNA) stock surged around 13% on Friday, hitting $67.50 and putting the stock on pace for its highest close since September 2024. The move made MRNA the top performer in the S&P 500 for the session. At one point during the day, the stock was up nearly 15%, touching close to $69.

Moderna, Inc., MRNA

The catalyst was Moderna’s investor day, where the company laid out a broad expansion of its drug pipeline well beyond its COVID vaccine roots.

MRNA is now up roughly 42% over the past month, a sign that investor sentiment has been shifting.

The headline announcement was Moderna’s first in vivo CAR-T program, called mRNA-6007. The company plans to begin clinical development in 2027, initially targeting B-cell-mediated autoimmune diseases, including systemic lupus erythematosus.

In vivo CAR-T therapy modifies a patient’s T-cells directly inside the body, making it more efficient and cheaper than traditional ex vivo methods that require cells to be extracted, altered in a lab, and then reinfused.

Moderna is not alone in chasing this technology. Eli Lilly moved earlier this year to acquire Orna Therapeutics specifically for its in vivo CAR-T platform. Lilly itself gained 6% on Friday, helped by a separate positive ruling from European regulators on its oral cancer drug.

A Pipeline Built in Three Horizons

Moderna outlined its future strategy across three distinct “horizons.” The first focuses on mature, near-term assets including existing commercial products and late-stage candidates.

Jefferies analyst Andrew Tsai expects the company could bring more than seven products to market across respiratory, oncology, and rare diseases within two years. That would be a major jump from its current three-vaccine lineup.

Tsai flagged Phase III melanoma data expected in the second half of 2026 as a key near-term catalyst, calling it “a major event” for the stock. He rates MRNA at Hold but raised his price target to $53 from $45.

Another closely watched program is mRNA-4194, Moderna’s first cancer prevention effort, aimed at patients with Lynch syndrome. The company is also advancing mRNA-1195, its multiple sclerosis candidate, which is expected to produce early data later in 2026.

Flu Vaccine Adds Another Catalyst

Outside oncology and autoimmune, Moderna’s flu vaccine candidate mRNA-1010 got a boost when an FDA advisory panel voted 9-0 in favor of approving it for adults aged 50 and older.

The FDA is set to make its final decision on August 5, 2026. A green light there would give the company another commercial product outside the COVID space.

Piper Sandler analyst Edward Tenthoff raised his price target to $77 from $69 and kept an Overweight rating, pointing to the progress displayed at investor day.

Despite the enthusiasm from some analysts, the broader Wall Street consensus sits at Hold, based on two Buys, 19 Holds, and three Sells over the past three months. The average price target stands at $45.42, which implies over 31% downside from current trading levels.

The post Moderna (MRNA) Stock Surges After Unveiling Cancer and Autoimmune Pipeline Push appeared first on CoinCentral.